New England Biolabs® Reveals Expanded NGS Sample Preparation Technology Pipeline at ASHG 2014

Ipswich, MA, USA (October 16, 2014) – At the 64th Annual Meeting of the American Society of Human Genetics (ASHG) in San Diego, CA, New England Biolabs (NEB®) will present a workshop and a series of posters highlighting novel technologies that advance sample preparation for next-generation sequencing. The workshop will include speakers from the Genome Sciences Centre, BC Cancer Agency and Yale University.

The workshop’s presentations, to occur Monday October 20th from 12:30 to 2:00PM in room 1A of the convention center, are as follows:

High Throughput Gel-free Library Construction from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens
Yongjun Zhao, Genome Sciences Centre, BC Cancer Agency

Immune-Seq Technology Introduction
Eileen Dimalanta, New England Biolabs, Inc.

High-throughput Immunoglobulin Sequencing Informatics: Insights into B cell Trafficking Patterns in Multiple Sclerosis
Jason Vander Heiden, Yale University

Effective Ribosomal RNA Depletion from Multiple Sample Types Including FFPE RNA
Fiona Stewart, New England Biolabs, Inc.

NEB will present six posters at the meeting, including methodologies in its development pipeline for FFPE DNA repair, target enrichment, immune repertoire sequencing and metatranscriptome enrichment. Additional topics include rRNA depletion from breast cancer FFPE samples and enrichment of microbiome DNA from a variety of sample types.

“As next-generation sequencing technologies advance and sequencing capacity increases, the need for effective sample preparation methods for a wider variety of applications, sample types and sample qualities increases. At New England Biolabs, we are committed to expanding the available range of high-performance sample preparation tools, and are pleased to highlight the breadth and depth of NEB’s novel technology development at ASHG again this year,” said Fiona Stewart, Product Marketing Manager, Next Generation Sequencing at NEB.



NEB Posters at ASHG


Recently Launched Technologies

  • #3370T — Selective depletion of abundant RNAs to enable transcriptome analysis of low input and highly degraded RNA from FFPE breast cancer samples.
  • #1699M — A method for selectively enriching microbial DNA from contaminating vertebrate host DNA.

Upcoming Technologies

  • #1703T — Optimized DNA extraction and repair improves the yield and quality of sequencing libraries derived from FFPE samples.

Pipeline Technologies

  • #1702M — Immune sequencing protocol for complete B-cell and T-cell repertoire sequencing.
  • #2531S — A new approach to target capture for genetic testing: a novel DNA enrichment method for next-generation sequencing applied to clinically-relevant genes.
  • #1683S — Development of a novel methodology for RNA-microbiome enrichment.


About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.

NEW ENGLAND BIOLABS®, NEB® AND NEBNEXT® are registered trademarks of  New England Biolabs, Inc.

Contact information:
Deana D. Martin, Ph.D.
Marketing Communications Manager
New England Biolabs
240 County Road
Ipswich, MA 01938
Tel: 978-380-7464
Email: [email protected]


10/16/2014

Return to News Listing